Oral Intake of Royal Jelly Has Protective Effects Against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial

Background: Although tyrosine kinase inhibitors (TKIs) are still recommended as the standard therapy in renal cell carcinoma (RCC), the high frequency of adverse events is a weakness of this therapy. Because royal jelly (RJ) possesses anti-inflammatory and antioxidant properties, we assessed its pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Araki, Kyohei, Miyata, Yasuyoshi, Ohba, Kojiro, Nakamura, Yuichiro, Matsuo, Tomohiro, Mochizuki, Yasushi, Sakai, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473390/
https://www.ncbi.nlm.nih.gov/pubmed/30577515
http://dx.doi.org/10.3390/medicines6010002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473390/
https://www.ncbi.nlm.nih.gov/pubmed/30577515
http://dx.doi.org/10.3390/medicines6010002

Ejemplares similares